|Bid||7.11 x 800|
|Ask||8.53 x 900|
|Day's Range||7.10 - 7.27|
|52 Week Range||5.13 - 9.57|
|Beta (3Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With FDA approval of its lead drug now just months away, a Israeli pharmaceutical outfit says it could more than double its Raleigh headcount before year-end.
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .
Just months after exiting a leadership position at another Triangle public company, one career researcher has been tapped as the CSO of another.
On the eve of filing for FDA approval of its lead drug, RedHill executives say the company is already building up its executive team in the Triangle.
RedHill Biopharma just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia – which means expansion of the company's Raleigh team.
Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.